USPTO serial 79311207
TICEBA STEM CELL EXPERTS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 4, 2022
- Examiner
- ROACH, APRIL K
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with TICEBA STEM CELL EXPERTS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sean K. Owens
Sean K. Owens Wood Herron & Evans LLP441 Vine Street, Suite 2700Cincinnati, OH 45202UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Stem cells for scientific or research use; cell growth media for growing cells for scientific use | ACTIVE | — |
| 005 | pharmaceutical drugs, namely pharmaceutical drugs for treatment of skin diseases, antibiotics, immune suppressants, anti-inflammatory pharmaceuticals; pharmaceutical drugs for treatment of disease and disorders of the respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the nervous system, the musculoskeletal system, the urinary system, the integumentary system, the reproductive system, for the treatment of blood diseases and disorders; pharmaceutical drugs for treatment of cancer, hormone replacement therapy preparations; pharmaceutical and veterinary preparations for treatment of vertigo, migraine, nausea, vomiting, for treatment of skin diseases, wound healing, pharmaceutical and veterinary preparations for treating diabetes, antidepressants; pharmaceutical preparations for anti-aging, pharmaceutical preparations namely antibiotics, vaccines; diagnostic agents for medical use; preparations for medical purposes, namely, for the treatment of skin diseases, allergy medication, herbal extracts for medical use, reagents for medical use; substances for medical use, namely, for regeneration of tissue and anti-inflammation; stem cells for medical purposes; stem cells for veterinary purposes; stem cells for aesthetic purposes, namely, for anti-aging, for use in dermatology procedures; somatic stem cell therapeutics, namely, for medical therapeutic use; fibroblasts for medical use; fibroblasts for aesthetic purposes, namely, for use in dermatology procedures; pharmaceutical implants, namely, implantable subcutaneous drug delivery devices sold filled with pharmaceutical for treatment of skin diseases, blood diseases, vertigo, nausea, vomiting, migraine, respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the musculoskeletal system, the urinary system, the integumentary system, and the reproductive system; surgical implants derived from stem cells, namely, surgical implants derived from living tissues and living stem cells; surgical implants derived from fibroblasts, namely, surgical implants comprised of living fibroblasts tissue cells; biological tissue for implantation, namely, implants comprising living tissues; cell growth media for growing cells for medical use; pharmaceutical preparations for tissue regeneration; vascular grafts; living tissue, namely, surgical implants comprised of living tissues; biotechnologically engineered tissue products, namely, living tissue cell sheets and plasters for wound healing and burns, biological eye lens grafts, bone grafts in the nature of biological bone tissue for grafting, biological tissue grafts, human allograft tissue | ACTIVE | — |
| 042 | Stem cell research; scientific research and development and medical research and development in the field of stem cells, vaccines and medications; scientific research, testing and analysis services in the field of regenerative medicine and tissue engineering, genetics and genetic engineering; scientific research for medical purposes; medical research; research and development of new products for others; consultancy in the field of pharmaceutical research; providing information on medical and scientific research on pharmaceutical products; biomedical research; preparation of reports relating to scientific research, namely, technical writing for others; research in the field of biotechnology; research in the field of gene therapy; research and development in the field of immunology; research and development in the field of antibodies; research and development in the field of antibody technology; research and development in the field of bacteriology; research and development in the field of gene expression systems; research and development in the field of vaccines; research and development services for the pharmaceutical industry; research and development services in the field of biotechnology; development of industrial processes, namely, engineering of industrial processes in the field of for packaging, storage and transport of human tissue and human adult ancestral cells, engineering of industrial processes to manufacture stem cells; industrial process research in the field of regenerative medicine and tissue engineering, chemical engineering | ACTIVE | — |
| 044 | Medical services relating to the removal, treatment, processing and preservation of human blood, cord blood, human cells and tissue, stem cells and bone marrow, also in the field of regenerative medicine, including tissue engineering; medical services in connection with the removal, treatment and processing of human tissue and stem cells, human tissue and stem cell bank services, including in the field of regenerative medicine, including tissue engineering; medical services relating to the cultivation and extraction of stem cells; medical services in connection with the cultivation and extraction of stem cells | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Dr. Christoph Ganss
- Other trademarks owned by Dr. Christoph Ganss
- Other trademarks owned by Dr. Christoph Ganss
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named TICEBA STEM CELL EXPERTS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 20, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 26, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 26, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 4, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 4, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 4, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 25, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 19, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 19, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 29, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 29, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 29, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 15, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 9, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 8, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 8, 2022 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Dec 22, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Dec 22, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 22, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 21, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 20, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 20, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 19, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 28, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 28, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 18, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 17, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 16, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| May 25, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 21, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 20, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |